Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 06-BG; Alkylade; BG; KRX 0402; NSC 638037; O6-benzylguanine

Latest Information Update: 01 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); The Pennsylvania State University
  • Developer ACCESS Oncology; National Cancer Institute (USA)
  • Class Antineoplastics; Chemosensitisers; Hypoxanthines; Small molecules
  • Mechanism of Action DNA repair enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cutaneous T-cell lymphoma
  • Discontinued Brain cancer; Glioblastoma; Glioma; Multiple myeloma; Sarcoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Feb 2017 National Cancer Institute completes a phase-I/II clinical trial in Cutaneous T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT00961220)
  • 10 Feb 2004 ACCESS Oncology has been acquired by Keryx Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top